Conditions: Multiple System Atrophy, MSA
Keywords: Multiple System Atrophy (MSA), PET imaging, myeloperoxidase (MPO) inhibitor
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 59
Healthy volunteers: no

Brief summary:
AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.

Detailed description:

Arms:
arm 1: Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio. arm 2: Subjects will be randomized to one of the two doses of AZD3241 or placebo in a 1:1:1 ratio.

Interventions: intervention 1: AZD3241 intervention 2: Placebo
Intervention descriptions: intervention 1: Drug: AZD3241 administered for 12 weeks orally as a tablet. intervention 2: Placebo to match AZD3241 administered for 12 weeks orally as a tablet.

Protocol document: